HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

Also called NCT04564872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 465 participants (enrolled count) (from the registry)
Sponsor
Sichuan Haisco Pharmaceutical Group Co., Ltd (from the registry)
Registry
  • NCT NCT04564872
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04564872. Randomized; double masking; primary purpose treatment. Start 2020-11-13 (actual); primary completion 2022-01-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HSK7653 10 mg Q2W
Intervention (Drug)
HSK7653 25 mg Q2W
Intervention (Drug)
Linagliptin 5 mg QD
Lead sponsor
Sichuan Haisco Pharmaceutical Group Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct04564872
Content hash
14407090d7ab836ca4185ecb9f343ef5ee346fe7cf022920182d645c96f18b79